# A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)

> **NCT02584543** · PHASE4 · COMPLETED · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 602 (actual)

## Conditions studied

- Hepatitis E
- Hepatitis B

## Interventions

- **BIOLOGICAL:** HEV vaccine
- **BIOLOGICAL:** HBV vaccine

## Key facts

- **NCT ID:** NCT02584543
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-08-25
- **Final completion:** 2016-08-25
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2017-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584543, "A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02584543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*